Conolidine’s analgesic effects stem from its conversation with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors in the central anxious process, conolidine modulates alternate molecular targets. A Science Innovations review observed that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7, whic